Clostridium Difficile Immunoassays Market

Clostridium Difficile Immunoassays Market - Global Industry Trend Analysis 2013 to 2017 and Forecast 2018 - 2028

Clostridium Difficile Immunoassays Market Segmented By Test Type such as Toxins A and B (EIA), Common antigen (common enzyme or GDH) Test, Toxigenic Anaerobic Culture Test, Tissue Cytotoxin Neutralization Assay

Industry: Healthcare

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Report Type: Ongoing

Report ID: PMRREP28204

Report Price

$ 4900*

Pre Book

Market Overview

Clostridium Difficile Immunoassays are specialized testing assay used in the detection of presence of Clostridium Difficile in the stool sample. The Clostridium Difficile Immunoassays is also used in defining bacterial and viral colonies for measure in treatments and evaluation. An approximately 310000 new cases of Clostridium Difficile are screened in the US per year. Additionally the Clostridium Difficile is the major reason of antibiotic related diarrhea.

Causing a prolong stomach associated conditions. The utilization of rapid test kits in the Clostridium Difficile Immunoassays is facilitating the diagnostic time and treatment seeking rate. Primarily most of the Clostridium Difficile infection are induced with pseudomembranous colitis where the associated use of antibiotic is form vulnerability to the normal flora of the body.

The high rate of hospitalization and prolong stays in the hospital is one of the major contributor for the high rate of Clostridium Difficile Immunoassays.

The major driving factor for Clostridium Difficile Immunoassays market is continuously increasing incidences of hospital visits, owning to increasing susceptibility to the infections and higher.  Adoption of antibiotic for the infection treatment is anticipated to fuel the demand for the Clostridium Difficile Immunoassays market.

As per data from center for disease control and prevention (CDC) nearly 15000 death are directly associated with the Clostridium Difficile infection in US alone marking as one of the substantial cause of the deaths in United States. The higher mortality is anticipated to fuel the demand for the Clostridium Difficile Immunoassays and aid in the growth of the Clostridium Difficile Immunoassays market.

The category of the fluoroquinolones are highly susceptible for the causing the degradation in the stomach and intestinal permeability. The higher demand for toxin B screening is anticipated to offer lucrative growth opportunity in the Clostridium Difficile Immunoassays market. However, low attrition rate Clostridium Difficile Immunoassays is projected to restrain the growth of the Clostridium Difficile Immunoassays Market.

Market Segmentation

Test type
  • Toxins A and B (EIA)
  • Common antigen (common enzyme or GDH) Test
  • Toxigenic Anaerobic Culture Test
  • Tissue Cytotoxin Neutralization Assay
Application
  • Drug testing in workplace
  • Employee drug testing
  • Border control
  • Roadside drug testing
  • Cholinesterase Monitoring
  • Clinical testing
End Users
  • Hospitals
  • Clinics
  • Household Settings
  • Diagnostics Laboratories
  • Research Centers

Regional Outlook

Geographically, global Clostridium Difficile Immunoassays market is segmented into seven key regions viz.  North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. North America leads the overall Clostridium Difficile Immunoassays Market.

Advancement in drug designing and availability of higher antibiotics, higher adoption to junk foods, increase awareness about antibiotic associated conditions, increase in hospital acquired infection awareness and favorable regulatory policies have improved the regulatory scenario for global Clostridium Difficile Immunoassays market in North America.

Additionally in East Asia region considerably higher market growth rate is expected due to constant growth in immunoassay market. Transversely affecting the Clostridium Difficile Immunoassays market.

Key Players

Some of the major key players competing in the global Clostridium Difficile Immunoassays Market are Hologic Inc., TECHLAB, Inc. Roche AG, Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Thermo Fisher Scientific Inc., Alere, Inc., Trinity Biotech, Baxter International Inc., Sanofi S.A., Summit Therapeutics, AstraZeneca Plc., and Novartis AG among others.

The report covers exhaustive analysis on:

  • Clostridium Difficile Immunoassays Market Segments
  • Clostridium Difficile Immunoassays Market Dynamics
  • Historical Actual Market Size, 2013 - 2017
  • Clostridium Difficile Immunoassays Market Size & Forecast 2018 to 2026
  • Clostridium Difficile Immunoassays Agents Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Clostridium Difficile Immunoassays Market Drivers and Restraints

Regional analysis includes:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceana
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance.

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate